Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

Authors

Emma Guttman-Yassky
Diamant Thaçi
Aileen L. Pangan
H Chih-Ho Hong
Kim A. Papp
Kristian Reich
Lisa A. Beck
Mohamed-Eslam F. Mohamed
Ahmed A. Othman
Jaclyn K. Anderson
Yihua Gu
Henrique D. Teixeira
Jonathan I. Silverberg, George Washington University

Document Type

Journal Article

Publication Date

11-28-2019

Journal

The Journal of Allergy and Clinical Immunology

DOI

10.1016/j.jaci.2019.11.025

Comments

Epub ahead of print

APA Citation

Guttman-Yassky, E., Thaçi, D., Pangan, A. L., Hong, H., Papp, K. A., Reich, K., Beck, L. A., Mohamed, M. F., Othman, A. A., Anderson, J. K., Gu, Y., Teixeira, H. D., & Silverberg, J. I. (2019). Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.. The Journal of Allergy and Clinical Immunology, (). http://dx.doi.org/10.1016/j.jaci.2019.11.025

Peer Reviewed

1